Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 31;19(1):20220990.
doi: 10.1515/biol-2022-0990. eCollection 2024.

MFAP5 inhibits the malignant progression of endometrial cancer cells in vitro

Affiliations

MFAP5 inhibits the malignant progression of endometrial cancer cells in vitro

Guanying Liang et al. Open Life Sci. .

Abstract

To investigate the biological role of MFAP5 in endometrial cancer (EC). HEC-1-A and Ishikawa cells overexpressing MFAP5 were created. Cell proliferation, apoptosis, migration, and invasion were evaluated using CCK8, colony formation, flow cytometry, and transwell assays. A western blot was used to analyze the expression of markers affiliated with the epithelial-mesenchymal transition process and AKT/mTOR pathway. As a result, MFAP5 was found to be down-regulated in EC. Overexpression of MFAP5 suppressed proliferation and promoted apoptosis of HEC-1-A and Ishikawa cells, as evidenced by the inhibition of cell viability and colony formation, and the increase in cell apoptosis rate. Besides, overexpression of MFAP5 attenuated the abilities of cell migration and invasion, as well as reduced MMP2 and MMP9 protein expression. Furthermore, E-cadherin protein level was elevated, while N-cadherin and α-SMA protein levels were decreased, and the phosphorylation of AKT and mTOR was reduced in cells overexpressing MFAP5. Our findings indicate that MFAP5 overexpression inhibits the malignant behaviors of EC cells, possibly by blocking the AKT/mTOR pathway, suggesting that MFAP5 may be a new therapeutic target for EC.

Keywords: AKT/mTOR; EMT; MFAP5; endometrial cancer; proliferation.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Authors state no conflict of interest.

Figures

Figure 1
Figure 1
MFAP5 is down-regulated in EC. (a) Analysis of MFAP5 expression in 174 UCEC tumors on TCGA. (b) MFAP5 protein expression in cells was analyzed with the western blot method. * p < 0.05, ** p < 0.01, and *** p < 0.001.
Figure 2
Figure 2
MFAP5 overexpression inhibits proliferation and promotes apoptosis of EC cells. (a) Overexpression efficiency of MFAP5 was detected by western blot. (b) Cell viability was evaluated using the CCK8 assay. (c) Cell clonogenic ability was examined by colony formation assay. (d) Apoptosis of cells was analyzed by flow cytometry. *** p < 0.001.
Figure 3
Figure 3
MFAP5 overexpression attenuates migration and invasion of EC cells. (a) Cell migration and invasion were assessed by transwell assays. (b) Western blot was used to detect MMP2 and MMP9 protein expression. ** p < 0.01 and *** p < 0.001.
Figure 4
Figure 4
MFAP5 overexpression suppresses EMT in EC cells. E-cadherin, N-cadherin, and α-SMA protein expression in cells was tested through western blot assays. *** p < 0.001.
Figure 5
Figure 5
MFAP5 overexpression inactivates the AKT/mTOR pathway. Protein expressions of AKT, p-AKT, mTOR, and p-mTOR were determined by western blot assays. * p < 0.05 and *** p < 0.001.
Figure 6
Figure 6
Schematic diagram of MFAP5 in EC via AKT/mTOR pathway. MFAP5 overexpression inhibited the activation of the AKT/mTOR pathway, thereby suppressing the proliferation, migration, invasion, and EMT of EC cells.

Similar articles

References

    1. Cai Y, Wang B, Xu W, Liu K, Gao Y, Guo C, et al. Endometrial cancer: genetic, metabolic characteristics, therapeutic strategies and nanomedicine. Curr Med Chem. 2021;28(42):8755–81. - PubMed
    1. Sun KX, Zheng RS, Zuo J, Zhang SW, Zeng HM, Wang SM, et al. The incidence and mortality of endometrial cancer in China, 2015. Zhonghua yi xue za zhi. 2022;102(26):1987–92. - PubMed
    1. Abdol Manap N, Ng BK, Phon SE, Abdul Karim AK, Lim PS, Fadhil M. Endometrial cancer in pre-menopausal women and younger: risk factors and outcome. Int J Environ Res Public Health. 2022;19(15):9059. - PMC - PubMed
    1. Wang N, Zhang J, Fan X, Ma J, He J, Kang S, et al. Identification of risk factors for the prognosis of Chinese patients with endometrial carcinoma. Medicine (Baltimore). 2021;100(38):e27305. - PMC - PubMed
    1. Chen W, Zheng R, Zhang S, Zeng H, Zuo T, Xia C, et al. Cancer incidence and mortality in China in 2013: an analysis based on urbanization level. Chin J Cancer Res = Chung-kuo yen cheng yen chiu. 2017;29(1):1–10. - PMC - PubMed

LinkOut - more resources